

Sam M Hanash

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4411526/publications.pdf>

Version: 2024-02-01

100
papers

11,494
citations

38742

50
h-index

34986

98
g-index

107
all docs

107
docs citations

107
times ranked

18087
citing authors

#	ARTICLE	IF	CITATIONS
1	SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1â€“Negative Lung Adenocarcinomas. <i>Journal of the National Cancer Institute</i> , 2022, 114, 290-301.	6.3	18
2	Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment. <i>Journal of Clinical Oncology</i> , 2022, 40, 876-883.	1.6	43
3	Proteomic Profiling of the Tumor Microenvironment. <i>Methods in Molecular Biology</i> , 2022, 2435, 157-167.	0.9	2
4	CES2 sustains HNF4Î± expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. <i>Molecular Metabolism</i> , 2022, 56, 101426.	6.5	14
5	Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma. <i>Cancers</i> , 2022, 14, 2543.	3.7	16
6	Contribution of a Blood-Based Protein Biomarker Panel to the Classification of Indeterminate Pulmonary Nodules. <i>Journal of Thoracic Oncology</i> , 2021, 16, 228-236.	1.1	22
7	Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. <i>Gastroenterology</i> , 2021, 160, 1373-1383.e6.	1.3	77
8	The length of the receiver operating characteristic curve and the two cutoff Youden index within a robust framework for discovery, evaluation, and cutoff estimation in biomarker studies involving improper receiver operating characteristic curves. <i>Statistics in Medicine</i> , 2021, 40, 1767-1789.	1.6	9
9	A MYC-Driven Plasma Polyamine Signature for Early Detection of Ovarian Cancer. <i>Cancers</i> , 2021, 13, 913.	3.7	15
10	Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients. <i>Npj Breast Cancer</i> , 2021, 7, 50.	5.2	6
11	Protein citrullination as a source of cancer neoantigens. , 2021, 9, e002549.		24
12	A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4969-e4980.	3.6	9
13	Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. <i>Nature Medicine</i> , 2021, 27, 141-151.	30.7	134
14	Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. <i>Gut</i> , 2021, 70, 2055-2065.	12.1	24
15	Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. <i>Gut</i> , 2020, 69, 18-31.	12.1	94
16	Association Between Plasma Diacetylspermine and Tumor Spermine Synthase With Outcome in Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2020, 112, 607-616.	6.3	40
17	Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer. <i>Nature Communications</i> , 2020, 11, 4279.	12.8	52
18	Plasma-Derived Extracellular Vesicles Convey Protein Signatures That Reflect Pathophysiology in Lung and Pancreatic Adenocarcinomas. <i>Cancers</i> , 2020, 12, 1147.	3.7	20

#	ARTICLE	IF	CITATIONS
19	Extracellular Vesicles Mediate B Cell Immune Response and Are a Potential Target for Cancer Therapy. <i>Cells</i> , 2020, 9, 1518.	4.1	35
20	Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis. <i>Cancers</i> , 2020, 12, 485.	3.7	9
21	Development of autoantibody signatures for common cancers. <i>Seminars in Immunology</i> , 2020, 47, 101388.	5.6	25
22	CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. <i>JCO Precision Oncology</i> , 2020, 4, 426-436.	3.0	9
23	Immune-Complexome Analysis Identifies Immunoglobulin-Bound Biomarkers That Predict the Response to Chemotherapy of Pancreatic Cancer Patients. <i>Cancers</i> , 2020, 12, 746.	3.7	6
24	A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 372-379.	6.3	79
25	Measuring human carboxylesterase 2 activity in pancreatic cancer patient-derived xenografts using a ratiometric fluorescent chemosensor. <i>Chemical Science</i> , 2019, 10, 8428-8437.	7.4	33
26	Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. <i>Nature</i> , 2019, 568, 410-414.	27.8	129
27	A plasma protein derived TGF β 2 signature is a prognostic indicator in triple negative breast cancer. <i>Npj Precision Oncology</i> , 2019, 3, 10.	5.4	18
28	Whole Genome-Derived Tiled Peptide Arrays Detect Prediagnostic Autoantibody Signatures in Non-Small-Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 1549-1557.	0.9	18
29	Testing the gene expression classification of the EMT spectrum. <i>Physical Biology</i> , 2019, 16, 025002.	1.8	35
30	Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. <i>Nature Communications</i> , 2019, 10, 254.	12.8	120
31	Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. <i>Nature</i> , 2019, 568, 161-184.		244
32	Detection and localization of surgically resectable cancers with a multi-analyte blood test. <i>Science</i> , 2018, 359, 926-930.	12.6	1,872
33	The Wide World of Molecular Profiling for Tumor Classification. <i>Clinical Chemistry</i> , 2018, 64, 743-744.	3.2	1
34	Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. <i>BJU International</i> , 2018, 121, 69-76.	2.5	10
35	JAK/STAT3-Regulated Fatty Acid β -Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. <i>Cell Metabolism</i> , 2018, 27, 136-150.e5.	16.2	519
36	Blood based biomarkers beyond genomics for lung cancer screening. <i>Translational Lung Cancer Research</i> , 2018, 7, 327-335.	2.8	33

#	ARTICLE	IF	CITATIONS
37	Interconnected feedback loops among ESRP1, HAS2, and CD44 regulate epithelial-mesenchymal plasticity in cancer. <i>APL Bioengineering</i> , 2018, 2, 031908.	6.2	71
38	Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins. <i>JAMA Oncology</i> , 2018, 4, e182078.	7.1	109
39	Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. <i>Cancer Immunology Research</i> , 2017, 5, 319-329.	3.4	25
40	Epithelial/mesenchymal plasticity: how have quantitative mathematical models helped improve our understanding?. <i>Molecular Oncology</i> , 2017, 11, 739-754.	4.6	64
41	Role of CPS1 in Cell Growth, Metabolism, and Prognosis in LKB1-Inactivated Lung Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw231.	6.3	69
42	Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw266.	6.3	116
43	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10202-10207.	7.1	438
44	HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. <i>Nature Communications</i> , 2017, 8, 451.	12.8	107
45	In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E7301-E7310.	7.1	88
46	Numb prevents a complete epithelial-to-mesenchymal transition by modulating Notch signalling. <i>Journal of the Royal Society Interface</i> , 2017, 14, 20170512.	3.4	104
47	MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway. <i>Cancer Research</i> , 2017, 77, 4414-4425.	0.9	85
48	Distinguishing mechanisms underlying EMT tristability. <i>Cancer Convergence</i> , 2017, 1, 2.	8.0	69
49	Plasma-derived extracellular vesicle proteins as a source of biomarkers for lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 95466-95480.	1.8	60
50	N1,N12-Diacetylspermine as a Blood Based Lung Cancer Biomarker. <i>Biochemistry and Analytical Biochemistry: Current Research</i> , 2016, 5, .	0.4	0
51	Stability of the hybrid epithelial/mesenchymal phenotype. <i>Oncotarget</i> , 2016, 7, 27067-27084.	1.8	367
52	Switching Roles of TGF- β 2 in Cancer Development: Implications for Therapeutic Target and Biomarker Studies. <i>Journal of Clinical Medicine</i> , 2016, 5, 109.	2.4	30
53	The Emerging Role of B Cells in Tumor Immunity. <i>Cancer Research</i> , 2016, 76, 5597-5601.	0.9	278
54	Lysyl Hydroxylase 2 Is Secreted by Tumor Cells and Can Modify Collagen in the Extracellular Space. <i>Journal of Biological Chemistry</i> , 2016, 291, 25799-25808.	3.4	58

#	ARTICLE	IF	CITATIONS
55	Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E1555-64.	7.1	174
56	Deciphering the complexity of the cancer proteome for diagnostic applications. Expert Review of Molecular Diagnostics, 2016, 16, 399-405.	3.1	5
57	Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer. PLoS ONE, 2016, 11, e0152300.	2.5	20
58	Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry. Metabolites, 2015, 5, 192-210.	2.9	69
59	Molecular Portraits of Epithelial, Mesenchymal, and Hybrid States in Lung Adenocarcinoma and Their Relevance to Survival. Cancer Research, 2015, 75, 1789-1800.	0.9	179
60	An Autoimmune Response Signature Associated with the Development of Triple-Negative Breast Cancer Reflects Disease Pathogenesis. Cancer Research, 2015, 75, 3246-3254.	0.9	33
61	Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. Journal of the National Cancer Institute, 2015, 107, .	6.3	72
62	Mass spectrometry based proteomics for absolute quantification of proteins from tumor cells. Methods, 2015, 81, 34-40.	3.8	13
63	MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas. Cancer Prevention Research, 2015, 8, 1112-1119.	1.5	25
64	Proteomic signatures associated with p53 mutational status in lung adenocarcinoma. Proteomics, 2014, 14, 2750-2759.	2.2	20
65	Proteomic profiling of the tumor microenvironment: recent insights and the search for biomarkers. Genome Medicine, 2014, 6, 12.	8.2	26
66	Autoantibody Signatures Involving Glycolysis and Spliceosome Proteins Precede a Diagnosis of Breast Cancer among Postmenopausal Women. Cancer Research, 2013, 73, 1502-1513.	0.9	57
67	Unleashing the Power of Proteomics to Develop Blood-Based Cancer Markers. Clinical Chemistry, 2013, 59, 119-126.	3.2	52
68	Circulating Pro-Surfactant Protein B as a Risk Biomarker for Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1756-1761.	2.5	24
69	Pro-Surfactant Protein B As a Biomarker for Lung Cancer Prediction. Journal of Clinical Oncology, 2013, 31, 4536-4543.	1.6	73
70	Concordant Release of Glycolysis Proteins into the Plasma Preceding a Diagnosis of ER+ Breast Cancer. Cancer Research, 2012, 72, 1935-1942.	0.9	27
71	Evaluation of Known Oncoantibodies, HER2, p53, and Cyclin B1, in Prediagnostic Breast Cancer Sera. Cancer Prevention Research, 2012, 5, 1036-1043.	1.5	57
72	Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer. Nature Reviews Clinical Oncology, 2011, 8, 142-150.	27.6	277

#	ARTICLE	IF	CITATIONS
73	Lung Cancer Signatures in Plasma Based on Proteome Profiling of Mouse Tumor Models. <i>Cancer Cell</i> , 2011, 20, 289-299.	16.8	158
74	Targets of the Tumor Suppressor <i>miR-200</i> in Regulation of the Epithelial-Mesenchymal Transition in Cancer. <i>Cancer Research</i> , 2011, 71, 7670-7682.	0.9	126
75	Integrated Proteomic Analysis of Human Cancer Cells and Plasma from Tumor Bearing Mice for Ovarian Cancer Biomarker Discovery. <i>PLoS ONE</i> , 2009, 4, e7916.	2.5	53
76	In-Depth Proteomics to Define the Cell Surface and Secretome of Ovarian Cancer Cells and Processes of Protein Shedding: Figure 1.. <i>Cancer Research</i> , 2009, 69, 728-730.	0.9	48
77	Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. <i>Genome Medicine</i> , 2009, 1, 47.	8.2	41
78	Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. <i>Nature Medicine</i> , 2008, 14, 822-827.	30.7	1,015
79	Increased Throughput and Reduced Carryover of Mass Spectrometry-Based Proteomics Using a High-Efficiency Nonsplit Nanoflow Parallel Dual-Column Capillary HPLC System. <i>Journal of Proteome Research</i> , 2008, 7, 2743-2755.	3.7	17
80	Integral Protein Microarrays for the Identification of Lung Cancer Antigens in Sera That Induce a Humoral Immune Response. <i>Molecular and Cellular Proteomics</i> , 2008, 7, 268-281.	3.8	58
81	Occurrence of Autoantibodies to Annexin I, 14-3-3 Theta and LAMR1 in Prediagnostic Lung Cancer Sera. <i>Journal of Clinical Oncology</i> , 2008, 26, 5060-5066.	1.6	178
82	Identification of 14-3-3 η as an Antigen that Induces a Humoral Response in Lung Cancer. <i>Cancer Research</i> , 2007, 67, 12000-12006.	0.9	79
83	Computational Proteomics Analysis System (CPAS): An Extensible, Open-Source Analytic System for Evaluating and Publishing Proteomic Data and High Throughput Biological Experiments. <i>Journal of Proteome Research</i> , 2006, 5, 112-121.	3.7	204
84	Identification of a Specific Vimentin isoform that Induces an Antibody Response in Pancreatic Cancer. <i>Biomarker Insights</i> , 2006, 1, 117727190600100.	2.5	21
85	Identification of a Specific Vimentin Isoform That Induces an Antibody Response in Pancreatic Cancer. <i>Biomarker Insights</i> , 2006, 1, 175-183.	2.5	18
86	Identification of Defensin $\alpha 6$ as a Potential Biomarker in Colon Adenocarcinoma. <i>Journal of Biological Chemistry</i> , 2005, 280, 8260-8265.	3.4	42
87	Proteomics Approaches to Identify Tumor Antigen Directed Autoantibodies as Cancer Biomarkers. <i>Disease Markers</i> , 2004, 20, 149-153.	1.3	48
88	An Autoantibody-Mediated Immune Response to Calreticulin Isoforms in Pancreatic Cancer. <i>Cancer Research</i> , 2004, 64, 5504-5510.	0.9	119
89	Integrated global profiling of cancer. <i>Nature Reviews Cancer</i> , 2004, 4, 638-644.	28.4	132
90	Development of Natural Protein Microarrays for Diagnosing Cancer Based on an Antibody Response to Tumor Antigens. <i>Journal of Proteome Research</i> , 2004, 3, 261-267.	3.7	127

#	ARTICLE	IF	CITATIONS
91	Molecular profiling of the immune response in colon cancer using protein microarrays: Occurrence of autoantibodies to ubiquitinC-terminal hydrolase L3. <i>Proteomics</i> , 2003, 3, 2108-2115.	2.2	126
92	Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. <i>Proteomics</i> , 2003, 3, 2200-2207.	2.2	85
93	Harnessing immunity for cancer marker discovery. <i>Nature Biotechnology</i> , 2003, 21, 37-38.	17.5	84
94	Accurate Molecular Classification of Human Cancers Based on Gene Expression Using a Simple Classifier with a Pathological Tree-Based Framework. <i>American Journal of Pathology</i> , 2003, 163, 1985-1995.	3.8	64
95	Protein profiles associated with survival in lung adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 13537-13542.	7.1	262
96	Discordant Protein and mRNA Expression in Lung Adenocarcinomas. <i>Molecular and Cellular Proteomics</i> , 2002, 1, 304-313.	3.8	813
97	A Distinct Repertoire of Autoantibodies in Hepatocellular Carcinoma Identified by Proteomic Analysis. <i>Molecular and Cellular Proteomics</i> , 2002, 1, 197-203.	3.8	151
98	Identification of Tumor-Associated Antigens Using Proteomics. <i>Technology in Cancer Research and Treatment</i> , 2002, 1, 257-262.	1.9	35
99	Proteomics approaches to uncover the repertoire of circulating biomarkers for breast cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2002, 7, 407-413.	2.7	37
100	Organ-Specific Molecular Classification of Primary Lung, Colon, and Ovarian Adenocarcinomas Using Gene Expression Profiles. <i>American Journal of Pathology</i> , 2001, 159, 1231-1238.	3.8	180